← All trials
NCT05951647
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 11, 2023
- Primary completion
- Oct 31, 2023
- Completion date
- Nov 30, 2023
- First posted
- Jul 19, 2023
- Last posted
- Jul 19, 2023
- Enrollment
- 60
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alexandria UniversityLead sponsor
- Alexandria UniversityOverall official - principal investigator
- Alexandria UniversityOverall official - principal investigator
- Alexandria UniversityOfficial
- Alexandria UniversityOfficial
- Alexandria UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.